MVASI® IS APPROVED FOR THE TREATMENT OF 5 DIFFERENT CANCER TYPES1
For information about your specific diagnosis, please make a selection below:
YOUR DOCTOR HAS SAID THAT YOU HAVE CERVICAL CANCER (CC)
Cervical cancer begins in the cells lining the cervix, which is the lower part of the uterus. Cancer occurs when the cervix develops precancerous cells that gradually turn into cancerous cells, which can spread to other areas of the body.2
CERVICAL CANCERS AND CERVICAL PRECANCERS ARE CLASSIFIED BY HOW THEY LOOK UNDER A MICROSCOPE:2
Squamous cell carcinomas
make up about 9 out of 10 cervical cancers. They develop on the outside of the cervix.
include most other cervical cancers. Cervical adenocarcinomas seem to have become more common in the past 20–30 years.
are less common cervical cancers that have features of both squamous cell carcinomas and adenocarcinomas.
WORKING WITH YOUR CERVICAL CANCER DOCTORS AND SPECIALISTS
Because cervical cancer can impact you and your loved ones' lives, it is important to work closely with your health care team. If you have questions, reach out to your doctor’s office directly for more information.
Links to the following organizations are provided for additional information and support, but should not be considered as an endorsement of MVASI® by these organizations.
VISIT THESE WEBSITES FOR MORE INFORMATION ABOUT CERVICAL CANCER
Important Safety Information
Possible serious side effects
Everyone reacts differently to MVASI® therapy. So, it's important to know what the side effects are. Although some people may have a life-threatening side effect, most do not. Your doctor will stop treatment if any serious side effects occur. Be sure to contact your health care team if there are any signs of these side effects.
Side effects seen most often
In clinical studies across different types of cancer, some patients experienced the following side effects:
MVASI® is not for everyone
Talk to your doctor if you are:
For more information about your treatment or condition, talk to your doctor.
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Amgen at 1-800-772-6436.
Please see full Product Information for additional Important Safety Information.
Metastatic Colorectal Cancer (mCRC)
MVASI® is approved to treat metastatic colorectal cancer (mCRC) for:
MVASI® is not approved for use after the primary treatment of colon cancer that has not spread to other parts of the body.
Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
MVASI®, in combination with carboplatin and paclitaxel, is approved to treat advanced non-squamous non-small cell lung cancer (NSCLC) in people who have not received chemotherapy for their advanced disease.
Recurrent Glioblastoma (rGBM)
MVASI® is approved to treat recurrent glioblastoma in adults.
Metastatic Renal Cell Carcinoma (mRCC)
MVASI®, used with interferon alfa, is approved to treat metastatic kidney cancer (mRCC).
Advanced Cervical Cancer (CC)
MVASI®, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is approved to treat persistent, recurrent, or metastatic cancer of the cervix.
Ovarian Cancer (OC)
MVASI®, in combination with carboplatin and paclitaxel, followed by Avastin alone, is used for the treatment of patients with advanced (Stage III or IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgery.
MVASI®, in combination with paclitaxel, pegylated liposomal doxorubicin or topotecan, is approved to treat platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer in women who received no more than two prior chemotherapy treatments.
MVASI®, either in combination with carboplatin and paclitaxel or with carboplatin and gemcitabine, followed by Avastin alone, is approved for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
References: 1. MVASI® (bevacizumab-awwb) Prescribing Information, Amgen. 2. American Cancer Society. What is cervical cancer?Accessed March 2, 2020.